Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis

9 Jan 2023

Abstract excerpt

Background: The pharmacokinetic/pharmacodynamics (PK/PD) target derived from the hollow-fiber system model for linezolid for treatment of the multidrug-resistant tuberculosis (MDR-TB) requires clinical validation. Therefore, this study aimed to develop a population PK model for linezolid when administered as part of a standardized treatment regimen, to identify the PK/PD threshold associated with successful...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimicrobial Resistance in Staphylococcus
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36699070
DOI: 10.3389/fphar.2022.1032674

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosisPMID 36699070Read ↗

Establishing a framework for human dose prediction in anti-tuberculosis drug developmentSemantic proximity Read ↗

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First StepsSemantic proximity Read ↗

Predicting early bactericidal activity of tuberculosis drug combinations using a translational pharmacokinetic-pharmacodynamic modeling approachSemantic proximity Read ↗

Lesion penetration predicts tuberculosis regimen success: a validated translational tool for de-risking late-stage drug developmentSemantic proximity Read ↗

Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.Semantic proximity Read ↗

Rising resistance to linezolid among critically ill patients calls for model-informed precision dosing in the empirical settingSemantic proximity Read ↗

Population Pharmacokinetics of Linezolid in Adults with Pulmonary TuberculosisSemantic proximity Read ↗

Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.Semantic proximity Read ↗

Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and TreatmentSemantic proximity Read ↗

Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis.Semantic proximity Read ↗

Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection ModelSemantic proximity Read ↗

The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.